Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Chou

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Pathology|August 28, 2014
EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancerMichelle Houang, Loretta Sioson, Adele Clarkson, et al.
European Journal of Clinical Investigation|November 2, 2024
Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patientsJosef E Gillson, Sooin Byeon, Angela Chou, et al.
Pathology|May 21, 2014
Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancerMichelle Houang, Christopher W Toon, Adele Clarkson, et al.
JCI Insight|January 11, 2022
A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4Qinghua Cao, Chunling Huang, Hao Yi, et al.
Cancers|August 8, 2020
Molecular Markers Guiding Thyroid Cancer ManagementCarolina Nylén, Robert Mechera, Isabella Maréchal-Ross, et al.
World Journal of Gastroenterology|July 1, 2014
Personalising pancreas cancer treatment: When tissue is the issueKatrin M Sjoquist, Venessa T Chin, Lorraine A Chantrill, et al.
The American Journal of Surgical Pathology|September 22, 2011
Renal tumors associated with germline SDHB mutation show distinctive morphologyAnthony J Gill, Nicholas S Pachter, Angela Chou, et al.
Human Pathology|August 7, 2018
ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumorsAngela Chou, Malinda Itchins, Philip R de Reuver, et al.
Cancers|July 27, 2022
The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic CancerChristopher B Nahm, John Turchini, Sumit Sahni, et al.
BMC Cancer|September 11, 2012
RON is not a prognostic marker for resectable pancreatic cancerCarole M Tactacan, David K Chang, Mark J Cowley, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Pathology|August 28, 2014
EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancerMichelle Houang, Loretta Sioson, Adele Clarkson, et al.
European Journal of Clinical Investigation|November 2, 2024
Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patientsJosef E Gillson, Sooin Byeon, Angela Chou, et al.
Pathology|May 21, 2014
Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancerMichelle Houang, Christopher W Toon, Adele Clarkson, et al.
JCI Insight|January 11, 2022
A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4Qinghua Cao, Chunling Huang, Hao Yi, et al.
Cancers|August 8, 2020
Molecular Markers Guiding Thyroid Cancer ManagementCarolina Nylén, Robert Mechera, Isabella Maréchal-Ross, et al.
World Journal of Gastroenterology|July 1, 2014
Personalising pancreas cancer treatment: When tissue is the issueKatrin M Sjoquist, Venessa T Chin, Lorraine A Chantrill, et al.
The American Journal of Surgical Pathology|September 22, 2011
Renal tumors associated with germline SDHB mutation show distinctive morphologyAnthony J Gill, Nicholas S Pachter, Angela Chou, et al.
Human Pathology|August 7, 2018
ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumorsAngela Chou, Malinda Itchins, Philip R de Reuver, et al.
Cancers|July 27, 2022
The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic CancerChristopher B Nahm, John Turchini, Sumit Sahni, et al.
BMC Cancer|September 11, 2012
RON is not a prognostic marker for resectable pancreatic cancerCarole M Tactacan, David K Chang, Mark J Cowley, et al.
Pageof 12